Global Necrotising Enterocolitis 麻豆原创 2024 by Company, Regions, Type and Application, Forecast to 2030

Publication ID:

GIR112403808

Publication Date:

November 28, 2024

Pages:

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Necrotising Enterocolitis market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
Necrotizing enterocolitis (NEC) is a devastating disease that affects mostly the intestine of premature infants. The wall of the intestine is invaded by bacteria, which cause local infection and inflammation that can ultimately destroy the wall of the bowel (intestine). Such bowel wall destruction can lead to perforation of the intestine and spillage of stool into the infant鈥檚 abdomen, which can result in an overwhelming infection and death.
Treatment of Necrotising Enterocolitis consists primarily of supportive care including providing bowel rest by stopping enteral feeds, gastric decompression with intermittent suction, fluid repletion to correct electrolyte abnormalities and third-space losses, support for blood pressure, parenteral nutrition, and prompt antibiotic therapy.
The report includes an overview of the development of the Necrotising Enterocolitis industry chain, the market status of Hospital & Clinic (Stage I, Stage II), Diagnostic Center (Stage I, Stage II), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Necrotising Enterocolitis.
Regionally, the report analyzes the Necrotising Enterocolitis markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Necrotising Enterocolitis market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Necrotising Enterocolitis market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Necrotising Enterocolitis industry.
The report involves analyzing the market at a macro level:
麻豆原创 Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Stage I, Stage II).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Necrotising Enterocolitis market.
Regional Analysis: The report involves examining the Necrotising Enterocolitis market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
麻豆原创 Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Necrotising Enterocolitis market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Necrotising Enterocolitis:
Company Analysis: Report covers individual Necrotising Enterocolitis players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Necrotising Enterocolitis This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital & Clinic, Diagnostic Center).
Technology Analysis: Report covers specific technologies relevant to Necrotising Enterocolitis. It assesses the current state, advancements, and potential future developments in Necrotising Enterocolitis areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Necrotising Enterocolitis market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
麻豆原创 Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
麻豆原创 Segmentation
Necrotising Enterocolitis market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
麻豆原创 segment by Type
Stage I
Stage II
Stage III
麻豆原创 segment by Application
Hospital & Clinic
Diagnostic Center
麻豆原创 segment by players, this report covers
GlaxoSmithKline
Pfizer
Eli Lilly And Company
Bayer HealthCare
Becton, Dickinson And Company
Bristol-Myers Squibb Company
Medtronic
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Necrotising Enterocolitis product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Necrotising Enterocolitis, with revenue, gross margin and global market share of Necrotising Enterocolitis from 2019 to 2024.
Chapter 3, the Necrotising Enterocolitis competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Necrotising Enterocolitis market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Necrotising Enterocolitis.
Chapter 13, to describe Necrotising Enterocolitis research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope of Necrotising Enterocolitis
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Necrotising Enterocolitis by Type
1.3.1 Overview: Global Necrotising Enterocolitis 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Necrotising Enterocolitis Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Stage I
1.3.4 Stage II
1.3.5 Stage III
1.4 Global Necrotising Enterocolitis 麻豆原创 by Application
1.4.1 Overview: Global Necrotising Enterocolitis 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital & Clinic
1.4.3 Diagnostic Center
1.5 Global Necrotising Enterocolitis 麻豆原创 Size & Forecast
1.6 Global Necrotising Enterocolitis 麻豆原创 Size and Forecast by Region
1.6.1 Global Necrotising Enterocolitis 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Necrotising Enterocolitis 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Necrotising Enterocolitis 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Necrotising Enterocolitis 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Necrotising Enterocolitis 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Necrotising Enterocolitis 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Necrotising Enterocolitis 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 GlaxoSmithKline
2.1.1 GlaxoSmithKline Details
2.1.2 GlaxoSmithKline Major Business
2.1.3 GlaxoSmithKline Necrotising Enterocolitis Product and Solutions
2.1.4 GlaxoSmithKline Necrotising Enterocolitis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 GlaxoSmithKline Recent Developments and Future Plans
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business
2.2.3 Pfizer Necrotising Enterocolitis Product and Solutions
2.2.4 Pfizer Necrotising Enterocolitis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Pfizer Recent Developments and Future Plans
2.3 Eli Lilly And Company
2.3.1 Eli Lilly And Company Details
2.3.2 Eli Lilly And Company Major Business
2.3.3 Eli Lilly And Company Necrotising Enterocolitis Product and Solutions
2.3.4 Eli Lilly And Company Necrotising Enterocolitis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Eli Lilly And Company Recent Developments and Future Plans
2.4 Bayer HealthCare
2.4.1 Bayer HealthCare Details
2.4.2 Bayer HealthCare Major Business
2.4.3 Bayer HealthCare Necrotising Enterocolitis Product and Solutions
2.4.4 Bayer HealthCare Necrotising Enterocolitis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Bayer HealthCare Recent Developments and Future Plans
2.5 Becton, Dickinson And Company
2.5.1 Becton, Dickinson And Company Details
2.5.2 Becton, Dickinson And Company Major Business
2.5.3 Becton, Dickinson And Company Necrotising Enterocolitis Product and Solutions
2.5.4 Becton, Dickinson And Company Necrotising Enterocolitis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Becton, Dickinson And Company Recent Developments and Future Plans
2.6 Bristol-Myers Squibb Company
2.6.1 Bristol-Myers Squibb Company Details
2.6.2 Bristol-Myers Squibb Company Major Business
2.6.3 Bristol-Myers Squibb Company Necrotising Enterocolitis Product and Solutions
2.6.4 Bristol-Myers Squibb Company Necrotising Enterocolitis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
2.7 Medtronic
2.7.1 Medtronic Details
2.7.2 Medtronic Major Business
2.7.3 Medtronic Necrotising Enterocolitis Product and Solutions
2.7.4 Medtronic Necrotising Enterocolitis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Medtronic Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Necrotising Enterocolitis Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Necrotising Enterocolitis by Company Revenue
3.2.2 Top 3 Necrotising Enterocolitis Players 麻豆原创 Share in 2023
3.2.3 Top 6 Necrotising Enterocolitis Players 麻豆原创 Share in 2023
3.3 Necrotising Enterocolitis 麻豆原创: Overall Company Footprint Analysis
3.3.1 Necrotising Enterocolitis 麻豆原创: Region Footprint
3.3.2 Necrotising Enterocolitis 麻豆原创: Company Product Type Footprint
3.3.3 Necrotising Enterocolitis 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Necrotising Enterocolitis Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Necrotising Enterocolitis 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global Necrotising Enterocolitis Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global Necrotising Enterocolitis 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America Necrotising Enterocolitis Consumption Value by Type (2019-2030)
6.2 North America Necrotising Enterocolitis Consumption Value by Application (2019-2030)
6.3 North America Necrotising Enterocolitis 麻豆原创 Size by Country
6.3.1 North America Necrotising Enterocolitis Consumption Value by Country (2019-2030)
6.3.2 United States Necrotising Enterocolitis 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Necrotising Enterocolitis 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Necrotising Enterocolitis 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Necrotising Enterocolitis Consumption Value by Type (2019-2030)
7.2 Europe Necrotising Enterocolitis Consumption Value by Application (2019-2030)
7.3 Europe Necrotising Enterocolitis 麻豆原创 Size by Country
7.3.1 Europe Necrotising Enterocolitis Consumption Value by Country (2019-2030)
7.3.2 Germany Necrotising Enterocolitis 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Necrotising Enterocolitis 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Necrotising Enterocolitis 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Necrotising Enterocolitis 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Necrotising Enterocolitis 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Necrotising Enterocolitis Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Necrotising Enterocolitis Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Necrotising Enterocolitis 麻豆原创 Size by Region
8.3.1 Asia-Pacific Necrotising Enterocolitis Consumption Value by Region (2019-2030)
8.3.2 China Necrotising Enterocolitis 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Necrotising Enterocolitis 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Necrotising Enterocolitis 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Necrotising Enterocolitis 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Necrotising Enterocolitis 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Necrotising Enterocolitis 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Necrotising Enterocolitis Consumption Value by Type (2019-2030)
9.2 South America Necrotising Enterocolitis Consumption Value by Application (2019-2030)
9.3 South America Necrotising Enterocolitis 麻豆原创 Size by Country
9.3.1 South America Necrotising Enterocolitis Consumption Value by Country (2019-2030)
9.3.2 Brazil Necrotising Enterocolitis 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Necrotising Enterocolitis 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Necrotising Enterocolitis Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Necrotising Enterocolitis Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Necrotising Enterocolitis 麻豆原创 Size by Country
10.3.1 Middle East & Africa Necrotising Enterocolitis Consumption Value by Country (2019-2030)
10.3.2 Turkey Necrotising Enterocolitis 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Necrotising Enterocolitis 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Necrotising Enterocolitis 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Necrotising Enterocolitis 麻豆原创 Drivers
11.2 Necrotising Enterocolitis 麻豆原创 Restraints
11.3 Necrotising Enterocolitis Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Necrotising Enterocolitis Industry Chain
12.2 Necrotising Enterocolitis Upstream Analysis
12.3 Necrotising Enterocolitis Midstream Analysis
12.4 Necrotising Enterocolitis Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Companies Mentioned:

GlaxoSmithKline
Pfizer
Eli Lilly And Company
Bayer HealthCare
Becton, Dickinson And Company
Bristol-Myers Squibb Company
Medtronic

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.